NASDAQ:LYRA Lyra Therapeutics (LYRA) Stock Price, News & Analysis $0.04 0.00 (0.00%) As of 08/18/2026 03:32 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Lyra Therapeutics Stock (NASDAQ:LYRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lyra Therapeutics alerts:Sign Up Key Stats Today's Range$0.02▼$0.0450-Day Range$0.04▼$0.7152-Week Range$0.00▼$8.75Volume5,235 shsAverage Volume50,472 shsMarket Capitalization$63.01 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects. The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS). LYR-210 is currently advancing through pivotal Phase 3 clinical trials, following positive Phase 2 data demonstrating significant improvements in symptom control and quality of life measures. In addition, Lyra is developing LYR-220 for chronic obstructive pulmonary disease (COPD) and exploring other respiratory indications, all based on its sustained-release implant technology. Founded in 2015 and headquartered in Lynnfield, Massachusetts, Lyra Therapeutics operates research and development facilities in the United States. The company is led by President and Chief Executive Officer Bryan J. Bork, supported by a management team with extensive expertise in drug delivery, drug development and regulatory strategy. As Lyra advances its pipeline through clinical development, it seeks to establish partnerships for commercial manufacturing and expand its platform into additional ENT and respiratory disease areas.AI Generated. May Contain Errors. Read More Receive LYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LYRA Stock News HeadlinesLyra Therapeutics Ends Major Office Sublease AgreementApril 17, 2026 | tipranks.comLyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SECApril 17, 2026 | globenewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.August 19 at 1:00 AM | Banyan Hill Publishing (Ad)After layoffs, Lyra Therapeutics exits Watertown and Waltham leasesApril 14, 2026 | bizjournals.comTreating allergic fungal rhinosinusitis in childrenApril 8, 2026 | msn.comLyra Therapeutics Withdraws Nasdaq Appeal, Faces Imminent DelistingMarch 16, 2026 | tipranks.comLyra Therapeutics (LYRA) price target decreased by 30.43% to 16.32February 4, 2026 | msn.comLyra Therapeutics suspends further development of LYR-210January 13, 2026 | finance.yahoo.comSee More Headlines LYRA Stock Analysis - Frequently Asked Questions How have LYRA shares performed this year? Lyra Therapeutics' stock was trading at $3.08 at the beginning of the year. Since then, LYRA shares have decreased by 98.8% and is now trading at $0.0355. How were Lyra Therapeutics' earnings last quarter? Lyra Therapeutics, Inc. (NASDAQ:LYRA) issued its quarterly earnings data on Wednesday, November, 12th. The company reported ($3.38) earnings per share for the quarter, topping analysts' consensus estimates of ($5.98) by $2.60. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.21 million. Lyra Therapeutics had a negative net margin of 5,491.17% and a negative trailing twelve-month return on equity of 1,010.91%. When did Lyra Therapeutics' stock split? Shares of Lyra Therapeutics reverse split before market open on Wednesday, May 28th 2025.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did Lyra Therapeutics IPO? Lyra Therapeutics (LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Lyra Therapeutics? Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE). Company Calendar Last Earnings11/12/2025Today8/19/2026Next Earnings (Estimated)8/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (27m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 LYRA's financial health is in the Red zone, according to TradeSmith. LYRA has been in this zone for over 27 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:LYRA CIK1327273 Webwww.lyratherapeutics.com Phone617-393-4600FaxN/AEmployees50Year Founded2005Profitability EPS (Trailing Twelve Months)($19.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$93.43 million Net Margins-5,491.17% Pretax Margin-5,488.67% Return on Equity-1,010.91% Return on Assets-58.92% Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio2.43 Sales & Book Value Annual Sales$600 thousand Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$8.86 per share Price / Book0.00Miscellaneous Outstanding Shares1,775,000Free Float1,717,000Market Cap$63.01 thousand OptionableNo Data Beta0.72 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:LYRA) was last updated on 8/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
